Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (May 2021)
28 slides from Myomo's investor presentation, May 2021
Slide 1: Conquering Upper Limb Paralysis with Wearable Medical Robotics
Paul R. Gudonis, Chairman and CEO David Henry, CFO Investor Presentation May 2021 Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Compan
Slide 3: Company Overview
Company Overview We design, manufacture and provide Only commercially available device of its the MyoPro™, a wearable medical kind with FDA registration, government robotic device that restores and private reimbursement and CE mark movement and function of paralyzed arms and hands Lightweight and po
Slide 4: Investment Highlights
Investment Highlights Large unmet medical need and potential market expansion through product line extensions • Patient Population with Chronic Arm Paralysis = Approx. 3M in US • New Incidences in US each year = Approx. 250K due to new strokes, other neuro conditions • Worldwide need: Prevalence =
Slide 5: If You Know People, You Probably Know Someone who needs a MyoPro
If You Know 100 People, You Probably Know Someone who needs a MyoPro NYSE American: MYO 5
Slide 6: A Large Unmet Need: Sizing the Market Opportunity
A Large Unmet Need: Sizing the Market Opportunity Prevalence Population Addressable Market (Chronic Arm Paralysis) New 6 - 12 mos. incidences: Rehab Therapy Stroke US: 800,000 Spinal Cord Injury Living Medically Insurance Patient strokes / yr. Brachial Plexus At Home Qualified Reimbursement Interest
Slide 7: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t
Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, portable ➢ Saebo ➢ Electrical stimulation device to restore (Bioness) ➢ Stationary robotics function for use
Slide 8: MyoPro Users and Value Propositions
MyoPro Users and Value Propositions Bettina Lucinda Igal Dave • Skiing accident @ age • Stroke during brain tumor operation • No use of right arm, • US veteran, arm 15 led to brachial plexus • Restored use of arm and hand 4 years post-stroke paralyzed due to stroke injury • Able to return to work •
Slide 9: Myomo’s Technology Leadership
Myomo’s Technology Leadership Operating at the Intersection of 3 Neuroscience Robotics Scientific and Engineering Disciplines Software • Brain-Computer Interface via EMG Sensors • Wearable Robotics • Advanced Control Algorithms • Patent Portfolio For EMG-Controlled Orthotics Extended to 2039 NYSE Am
Slide 10: MyoPro Powered Arm Brace: How it Works
MyoPro Powered Arm Brace: How it Works Brain Movement Signal Signal EMG Processing Sensor NYSE American: MYO 10
Slide 11: Competitive Positioning
Competitive Positioning Prosthetics Orthotics (Braces) Only commercially available upper limb product line to restore function Upper Upper Limb Limb Products Products Foot Drop Stance Control Exoskeletons Wheelchair Lower Limb Lower Products Limb Products Unit Volume * Orthotics and Prosthetics NYSE
Slide 12: Trends in Healthcare Fueling Myomo’s Growth
Trends in Healthcare Fueling Myomo’s Growth Large and Growing Pool of Patient Candidates - Stroke Incidence increases with Aging Population, Underlying Health Conditions Centralized Decentralized Patient Care - From Rehab Clinic to At Home Use In-person Visits Telehealth - Enabled by broadband
Slide 13: Go to Market Approach: Direct Billing and Provider
Go to Market Approach: Direct Billing and Provider Lead Delivery Generation Reimbursement & & Approval Payment Evaluations Mass Customization Common Robotic Components Custom Fabricated MyoPro NYSE American: MYO 12
Slide 14: Filling the Pipeline via Digital Marketing and Telehealth
Filling the Pipeline via Digital Marketing and Telehealth Facebook Marketing Ad TeleHealth Evaluation Digital marketing to patients and families (B2C) Moved online: faster, more convenient, less costly NYSE American: MYO 14
Slide 15: Meet Sara Groves – MyoPro User on TikTok
Meet Sara Groves – MyoPro User on TikTok Click here to watch Sara’s TikTok video. NYSE American: MYO 15
Slide 16: Expanding list of Payers Reimbursing for a MyoPro
Expanding list of Payers Reimbursing for a MyoPro Commercial Payers Military Medicare • Approvals on a case • Approved for Vets • New HCPCS codes in by case basis • > 40 VAMC’s have 2019 • Over 90% of new ordered MyoPro’s • Medicare Advantage cases are now Direct claims paid Billing by Myomo • Part
Slide 17: Myomo Now a Certified Medicare Provider
Myomo Now a Certified Medicare Provider Once coverage and fee are determined by CMS, Myomo will be able to provide the MyoPro to Medicare Part B patients in 39 states Working on becoming certified in the remaining states Working on becoming a provider for patients covered by state Medicaid pla
Slide 18: Initial Steps to Address the Global Need
Initial Steps to Address the Global Need NYSE American: MYO 18
Slide 19: European Expansion Underway and New China JV
European Expansion Underway and New China JV Europe China Established Myomo footprint in Announced Myomo China JV with Europe – Myomo Europe GmbH Ryzur, medical device and rehab co. based in Germany Recruited O&P providers in Germany, Chinese partners providing capital, Denmark, UK, Italy lo
Slide 20: Recap of Recent News Announcements
Recap of Recent News Announcements ➢ MyoPro Featured on German TV Show CBS Sunday Morning (1/31) on research with MyoPro @ T Jefferson Univ Hospital ➢ MyoCare Program Introduced to Support Users ➢ Myomo Certified as a Medicare Provider ➢ VA Research Finds MyoPro Delivers Meaningful Improvements in
Slide 21: MyoPro Delivery and Payment: Shift to Direct Billing
MyoPro Delivery and Payment: Shift to Direct Billing Revenue Percent by Channel • Emphasis on the direct billing channel 100% results in higher average selling price and higher gross margin per unit 80% • International revenue expected to grow in the future as we capitalize on 60% favorable coverage
Slide 22: Backlog and Pipeline: Authorization to Revenue
Backlog: Authorization to Revenue - Near-Term Indicator Pipeline: Successful Evaluation to Authorization – Longer-Term Indicator Backlog Pipeline 180 162 160 1000 940 140 131 900 120 118 741 756 768 120 800 711 386 700 594 100 228 209 80 600 528 307 192 80 453 61 500 193 60 53 400 192 182 40 300 559
Slide 23: Q1 2021 Revenue Growth = 132% YoY
Q1 2021 Revenue Growth = 132% YoY Quarterly Revenue Annual Revenue 4,000,000 $M 7.6 3,500,000 3,000,000 2,500,000 3.8 2,000,000 1,500,000 2.4 1.6 1,000,000 1.0 500,000 0 2016 2017 2018 2019 2020 1Q 2Q 3Q 4Q 2016 2017 2018 2019 2020 2021 23
Slide 24: P&L and Key Balance Sheet Metrics
P&L and Key Balance Sheet Metrics P&L Actual Actual Actual Actual Key Balance Sheet Metrics ($000's) Q1'21 Q1'20 2020 2019 Actual Actual ($000's) Q1'21 Q4'20 Revenue $ 2,336 $ 1,008 $ 7,583 $ 3,838 COGS 623 319 2,600 1,421 Gross Profit 1,713 689 4,983 2,417 Cash $ 17,371 $ 12,241 Gross Margin 73.3%
Slide 25: Target: Achieve Cash Flow Breakeven in Q4 2021
Target: Achieve Cash Flow Breakeven in Q4 2021 Key Drivers Increasing # of Patient Candidates entering the Pipeline Continued Shift to Direct Billing = Higher ASP and Margin Demonstrating Operating Leverage: Q1 2021 Oper. Loss = $2.9M, Q1 2020 = $3.4M Grow Backlog of Authorized MyoPro’s for
Slide 26: Proven Technology & Healthcare Leadership
Proven Technology & Healthcare Leadership Management Team Members Board of Directors & Advisors Paul R. Gudonis Dr. Harry Kovelman Ross D. Zafonte, DO Chairman & CEO Chief Medical Officer Chair, SAB Scaled multiple tech co’s, largest from Track record of expanding patent Harvard Med. School, $5M to
Slide 27: Investment Highlights
Investment Highlights Large unmet medical need and potential market expansion through product line extensions • Patient Population with Chronic Arm Paralysis = Approx. 3M in US • New Incidences in US each year = Approx. 250K due to new strokes, other neuro conditions • Worldwide need: Prevalence =
Slide 28: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 NYSE American: MYO 28